Covered recipient · General Payments record
FLANNERY FARRELL
Physician Assistants & Advanced Practice Nursing Providers Advanced Practice Midwife
General Payments · PY2021
$233.28
- Reported across 16 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2021 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $233.28 | 16 |
By paying entity
PY2021 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Mylan Pharmaceuticals Inc. | $63.03 | 4 |
| Amgen Inc. | $54.73 | 4 |
| TherapeuticsMD, Inc. | $44.24 | 3 |
| Myovant Sciences Inc. | $17.16 | 1 |
| PFIZER INC. | $14.82 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $14.65 | 1 |
| Avion Pharmaceuticals | $13.61 | 1 |
| Exeltis, USA Inc. | $11.04 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2021 | $233.28 | 16 |
Payment records · PY2021 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $14.65 | 06/08/2021 | Food and Beverage | Undisputed | 01/23/2026 | 826012801 | CMS |
| Amgen Inc. | $13.32 | 08/12/2021 | Food and Beverage | Undisputed | 01/23/2026 | 826012805 | CMS |
| Amgen Inc. | $14.12 | 09/02/2021 | Food and Beverage | Undisputed | 01/23/2026 | 826012809 | CMS |
| Amgen Inc. | $12.64 | 10/07/2021 | Food and Beverage | Undisputed | 01/23/2026 | 826012813 | CMS |
| Avion Pharmaceuticals | $13.61 | 09/23/2021 | Food and Beverage | Undisputed | 01/23/2026 | 845426029 | CMS |
| Exeltis, USA Inc. | $11.04 | 08/24/2021 | Food and Beverage | Undisputed | 01/23/2026 | 806189141 | CMS |
| MAYNE PHARMA INC. | $14.65 | 08/17/2021 | Food and Beverage | Undisputed | 01/23/2026 | 849501723 | CMS |
| Mylan Pharmaceuticals Inc. | $19.10 | 06/15/2021 | Food and Beverage | Undisputed | 01/23/2026 | 965463339 | CMS |
| Mylan Pharmaceuticals Inc. | $15.80 | 07/15/2021 | Food and Beverage | Undisputed | 01/23/2026 | 965464309 | CMS |
| Mylan Pharmaceuticals Inc. | $13.81 | 09/16/2021 | Food and Beverage | Undisputed | 01/23/2026 | 965466183 | CMS |
| Mylan Pharmaceuticals Inc. | $14.32 | 10/13/2021 | Food and Beverage | Undisputed | 01/23/2026 | 965466903 | CMS |
| Myovant Sciences Inc. | $17.16 | 07/06/2021 | Food and Beverage | Undisputed | 01/23/2026 | 835002369 | CMS |
| PFIZER INC. | $14.82 | 11/17/2021 | Food and Beverage | Undisputed | 01/23/2026 | 833161757 | CMS |
| TherapeuticsMD, Inc. | $14.78 | 06/17/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844958217 | CMS |
| TherapeuticsMD, Inc. | $14.76 | 07/01/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844958221 | CMS |
| TherapeuticsMD, Inc. | $14.70 | 11/03/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844958227 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021
- Source files
- Dataset page · Bulk file · PY2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.